Elutia Inc. (NASDAQ:ELUT) Sees Significant Increase in Short Interest

Elutia Inc. (NASDAQ:ELUT) was the recipient of a significant increase in short interest during the month of March. As of March 31st, there was short interest totalling 17,000 shares, an increase of 32.8% from the March 15th total of 12,800 shares. Based on an average trading volume of 21,200 shares, the days-to-cover ratio is presently 0.8 days. Approximately 0.1% of the shares of the company are short sold.

Elutia Price Performance

Shares of ELUT stock opened at $2.99 on Monday. The stock has a market cap of $72.57 million, a P/E ratio of -1.42 and a beta of 0.51. The company has a fifty day moving average price of $3.37 and a two-hundred day moving average price of $2.56. Elutia has a one year low of $1.10 and a one year high of $4.19.

Elutia (NASDAQ:ELUT) last announced its quarterly earnings results on Thursday, March 7th. The company reported ($0.66) EPS for the quarter. The business had revenue of $5.88 million for the quarter. As a group, equities research analysts anticipate that Elutia will post -1.68 EPS for the current fiscal year.

Institutional Trading of Elutia

Hedge funds have recently modified their holdings of the stock. Alyeska Investment Group L.P. acquired a new stake in shares of Elutia during the 4th quarter worth about $1,062,000. Geode Capital Management LLC lifted its stake in shares of Elutia by 393.0% during the 2nd quarter. Geode Capital Management LLC now owns 69,569 shares of the company’s stock worth $164,000 after buying an additional 55,457 shares during the last quarter. Renaissance Technologies LLC lifted its stake in shares of Elutia by 175.7% during the 2nd quarter. Renaissance Technologies LLC now owns 60,416 shares of the company’s stock worth $143,000 after buying an additional 38,500 shares during the last quarter. Finally, Jane Street Group LLC acquired a new stake in shares of Elutia during the 1st quarter worth about $29,000. Institutional investors and hedge funds own 74.03% of the company’s stock.

About Elutia

Elutia Inc, a commercial-stage company, develops and commercializes drug-eluting biologics products for neurostimulation, wound care, and breast reconstruction in the United States. The company operates in three segments: Device Protection; Women's Health; and Cardiovascular. It offers CanGaroo Envelope, which is used to accommodate cardiac implantable electronic devices, such as pacemakers and internal defibrillators.